Neptune Launches Patent Infringement Litigation Against Aker Biomarine ASA, Enzymotec...

Thu Oct 6, 2011 8:01am EDT

* Reuters is not responsible for the content in this press release.

Neptune Launches Patent Infringement Litigation Against Aker Biomarine ASA,
Enzymotec Ltd., and Others

LAVAL, Quebec, Oct. 6, 2011 (GLOBE NEWSWIRE) -- Neptune Technologies and
Bioressources Inc. (Nasdaq:NEPT) (TSX-V:NTB) announced it has filed complaints
in the U.S. District Court for the District of Delaware alleging infringement of
its recently issued patent.

The action was filed by Neptune for infringement of its recently issued omega-3
composition patent against Aker Biomarine ASA, Aker Biomarine Antarctic USA,
Inc., and Schiff Nutritional International. Neptune has launched a separate
infringement action against Enzymotec Limited., Enzymotec USA, Inc., Mercola.com
Health Resources, LLC and Azantis, Inc.

"This US patent is robust and Neptune will move aggressively to enforce its
intellectual rights in relation to our competition," stated President & CEO
Henri Harland. He added that, "A significant amount of money has been invested
by shareholders to develop Neptune's intellectual property and we will protect
the company's assets. Neptune is the pioneer of this field and intends to justly
maintain its leadership."

Neptune's recently issued US patent (U.S. No. 8,030,348) covers novel omega-3
fatty acid phospholipid compositions suitable for human consumption, synthetic
and/or natural, including compositions extracted from marine and aquatic
biomasses. The 8,030,348 patent protects Neptune Krill Oil(TM) (NKO(R)) and also
covers amongst others, oils and powders extracted from krill, containing marine
phospholipids bonded to EPA and/or DHA, distributed and/or sold in the U.S.
market.

About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and
formulation of science-based and clinically proven novel phospholipid products
for the nutraceutical and pharmaceutical markets. The Company focuses on growing
consumer health markets including cardiovascular, inflammatory and neurological
diseases driven by consumers taking a more proactive approach to managing health
and preventing disease. The Company sponsors clinical trials aimed to
demonstrate its product health benefits and to obtain regulatory approval for
label health claims. Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals. Neptune's
products are marketed and distributed in over 20 countries worldwide.

About Acasti Pharma Inc.

Acasti Pharma (TSX-V:APO) is developing a product portfolio of proprietary novel
long-chain omega-3 phospholipids. Phospholipids are the major component of cell
membranes and are essential for all vital cell processes. They are one of the
principal constituents of High Density Lipoprotein (good cholesterol) and, as
such, play an important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the polyunsaturated
omega-3 fatty acids EPA and DHA, which have been shown to have substantial
health benefits and which are stabilized by astaxanthin, a potent antioxidant.
Acasti Pharma is focusing initially on treatments for chronic cardiovascular and
cardiometabolic conditions within the over-the-counter, medical food and
prescription drug markets.

About NeuroBioPharm Inc.

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a
clinical study for a medical food product with a multinational partner is
already initiated. The development of a prescription drug candidate is currently
in progress. Advanced clinical development and commercialization is planned to
be carried out with multinational partners.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release."

Statements in this press release that are not statements of historical or
current fact constitute "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities
laws. Such forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the actual results of
the Company to be materially different from historical results or from any
future results expressed or implied by such forward-looking statements. In
addition to statements which explicitly describe such risks and uncertainties,
readers are urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or "plans" to be
uncertain and forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that are described
from time to time in the Company's reports filed with the Securities and
Exchange Commission and the Canadian securities commissions.

CONTACT: Neptune Contact:
         Neptune Technologies & Bioressources Inc.
         Andre Godin, CFO
         +1.450.687.2262
         a.godin@neptunebiotech.com
         www.neptunebiotech.com

         CEOcast Contact:
         Dan Schustack
         +1 212-732-4300
         dschustack@ceocast.com
         www.ceocast.com

         Howard Group Contact:
         Dave Burwell
         (888) 221-0915
         dave@howardgroupinc.com
         www.howardgroupinc.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.